Key Highlights
- Trevi Therapeutics shares rose approximately 7.03 percent in pre-market trading to $19.80 from Wednesday's close of $18.50.
- The company reported a second quarter net loss of $0.11 per share, in line with consensus estimates.
- Trevi highlighted pipeline progress across its Haduvio chronic cough program spanning three indications in Phase 2b and Phase 3 trials.
- Cash and equivalents of approximately $319 million support the company's runway into 2029.
Shares Climb Despite In-Line Loss
Trevi Therapeutics, Inc. (NASDAQ:TRVI) traded up approximately 7.03 percent in pre-market activity, near $19.80 versus Wednesday's close of $18.50. The move follows a second quarter net loss of $0.11 per share matching consensus, with no revenue reported given the company's pre-commercial stage.
Multiple Trials Advancing
The company's lead asset, Haduvio, an oral extended-release chronic cough therapy, is progressing through several late-stage studies. The Phase 2b/3 Ocean-1 trial in IPF-related chronic cough and the Phase 2b Lake trial in refractory chronic cough are underway, with a new non-IPF interstitial lung disease study slated to begin later in 2026 and the Lake trial's sample-size re-estimation expected in the fourth quarter.
Cash Position Supports Extended Runway
Trevi reported approximately $319 million in cash, cash equivalents, and marketable securities, with the company reiterating that its runway extends into 2030, funding programs through Phase 3 and potential commercial launch.
Investor Sentiment Improving
Eleven covering analysts rate the stock a buy, with a mean price target implying more than 40 percent upside from recent levels. FMR LLC also recently disclosed an 8.8 percent passive stake in the company.
Conclusion
Trevi's pre-market gain despite reporting a loss in line with expectations suggests investors are looking past near-term financials toward the multi-year Haduvio timeline and its well-funded runway. With three trials now active or planned across distinct indications, the reaction points to confidence in the pipeline's breadth.


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...